How many stocks are there of Repligen?
The current number of stocks of Repligen is 56.38 M undefined.
Repligen Stocks 2024
Repligen Stocks
56.38 M
Ticker
RGEN
ISIN
US7599161095
WKN
870980
In 2024, Repligen had 56.38 M outstanding stocks, a 0% change from the 56.38 M stocks in the previous year.
The Repligen Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 56.38 |
| 2028e | 56.38 |
| 2027e | 56.38 |
| 2026e | 56.38 |
| 2025e | 56.38 |
| 2024e | 56.38 |
| 2023 | 56.38 |
| 2022 | 57.5 |
| 2021 | 57.3 |
| 2020 | 53.9 |
| 2019 | 49.2 |
| 2018 | 45.5 |
| 2017 | 39.2 |
| 2016 | 34.1 |
| 2015 | 33.6 |
| 2014 | 33.3 |
| 2013 | 32.4 |
| 2012 | 31.3 |
| 2011 | 30.8 |
| 2010 | 30.8 |
| 2009 | 30.8 |
| 2008 | 31.3 |
| 2007 | 31.3 |
| 2006 | 30.4 |
| 2005 | 30.7 |
| 2004 | 30.1 |
Repligen shares outstanding US7599161095 · 870980
The number of shares was Repligen in 2023 — This indicates how many shares 56.377 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Repligen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Repligen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Repligen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Repligen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 30.1 M Aktien |
| 2005 | 30.7 M Aktien |
| 2006 | 30.4 M Aktien |
| 2007 | 31.3 M Aktien |
| 2008 | 31.3 M Aktien |
| 2009 | 30.8 M Aktien |
| 2010 | 30.8 M Aktien |
| 2011 | 30.8 M Aktien |
| 2012 | 31.3 M Aktien |
| 2013 | 32.4 M Aktien |
| 2014 | 33.3 M Aktien |
| 2015 | 33.6 M Aktien |
| 2016 | 34.1 M Aktien |
| 2017 | 39.2 M Aktien |
| 2018 | 45.5 M Aktien |
| 2019 | 49.2 M Aktien |
| 2020 | 53.9 M Aktien |
| 2021 | 57.3 M Aktien |
| 2022 | 57.5 M Aktien |
| 2023 | 56.38 M Aktien |
| 2024e | 56.38 M Aktien |
| 2025e | 56.38 M Aktien |
| 2026e | 56.38 M Aktien |
| 2027e | 56.38 M Aktien |
| 2028e | 56.38 M Aktien |
| 2029e | 56.38 M Aktien |
Repligen Aktienanalyse
What does Repligen do?
Repligen Corp is an American company that was founded in 1981 and is headquartered in Waltham, Massachusetts. The company is a leading provider of products for the biopharmaceutical industry. It offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The history of Repligen Corp begins in the 1980s when the company was originally founded to produce human proteins for medical purposes. Over the years, the company expanded its business and focused on the production of purification solutions for the biopharmaceutical industry. Today, Repligen is an established company in this field and serves customers around the world. Business model: Repligen Corp is a leading provider of products and services for the biopharmaceutical industry. The company focuses on the development and manufacturing of products for the purification of proteins and antibodies. These products are used by biotech and pharmaceutical customers to improve the effectiveness and safety of their products in the clinical development process. Repligen Corp is generally able to achieve good prices for its products as they are high-quality products for a high-priced industry. The company is also interested in introducing new products to the market and expanding its customer base. Various divisions: Repligen Corp offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The company is divided into various divisions, including: 1. Chromaflow: Repligen's Chromaflow products offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. These products enable customers to test and develop their products faster and more effectively. 2. Protein A Adsorbent Resin: Repligen Corp offers a Protein A Adsorbent Resin used in biotherapy. It allows for highly efficient purification of therapeutics produced using Protein A. 3. Alternating Tangential Flow (ATF) Systems: Repligen's ATF system enables continuous cell culture of proteins and antibodies. This facilitates the production of biopharmaceutical products and shortens development time. 4. Process Analytical Technology (PAT): Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. It improves process control and reduces the risk of errors and failures. 5. Filtration products: Repligen's filtration products include disposable filters and microfiltration membranes. These products are used by customers in the biopharmaceutical industry for the purification of biological products. Products: Repligen Corp offers a wide range of innovative products and services to support the development of biological drugs. Here are some of the products offered by Repligen Corp: 1. Protein A Adsorbent Resin: This product is used in biotherapy and the biopharmaceutical industry to enable highly efficient purification of therapeutics produced using Protein A. 2. Alternating Tangential Flow (ATF) Systems: This system enables continuous cell culture of proteins and antibodies. It facilitates the production of biopharmaceutical products and shortens development time. 3. Chromaflow products: They offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. 4. PAT systems: Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. 5. Filtration products: Repligen's filtration products include disposable filters and membranes. These products are used by customers in the biopharmaceutical industry to purify biological products. In summary, Repligen Corp is an established company that focuses on the development and production of products and services for the biopharmaceutical industry. The company offers a wide range of innovative products that contribute to the acceleration and improvement of the development of biological drugs. With its long history and established reputation as a leading provider, Repligen Corp is a significant player in the biopharmaceutical industry. Repligen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Repligen's Shares Outstanding
Repligen's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Repligen’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Repligen’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Repligen’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Repligen stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Repligen are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Repligen evolved in recent years?
The number of shares of Repligen has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Repligen as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Repligen?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Repligen pay?
Over the past 12 months, Repligen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Repligen is expected to pay a dividend of 0 USD.
What is the dividend yield of Repligen?
The current dividend yield of Repligen is .
When does Repligen pay dividends?
Repligen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Repligen?
Repligen paid dividends every year for the past 0 years.
What is the dividend of Repligen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Repligen located?
Repligen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Repligen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Repligen from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.
When did Repligen pay the last dividend?
The last dividend was paid out on 11/5/2024.
What was the dividend of Repligen in the year 2023?
In the year 2023, Repligen distributed 0 USD as dividends.
In which currency does Repligen pay out the dividend?
The dividends of Repligen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Repligen stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Repligen
Our stock analysis for Repligen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repligen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
